Neuronetics has entered into an exclusive three‑year agreement with Elite DNA Behavioral Health to supply its NeuroStar Advanced Therapy System and Greenbrook platform services across more than 30 Elite DNA sites in Florida and Virginia.
Under the deal, Neuronetics will be the sole provider of transcranial magnetic stimulation (TMS) devices for all Elite DNA locations and will deliver fee‑based operational and patient‑support services through a newly formed subsidiary. Services include PHQ‑10 processing, TMS consultations and scheduling.
The partnership will begin with a pilot in the fourth quarter of 2025 and will expand to all sites in 2026. The collaboration is intended to increase treatment volume and broaden access for patients on Medicaid, Medicare and self‑pay plans.
Neuronetics’ CEO Keith J. Sullivan said the agreement expands the reach of its NeuroStar therapy through a scalable, systemized model of care. Elite DNA CEO Elizabeth Dosoretz said the partnership advances its mission to provide evidence‑based care in every community it serves.
The deal follows Neuronetics’ December 2024 acquisition of Greenbrook TMS, which created an integrated TMS treatment network. The partnership leverages the Greenbrook platform to convert device placement into recurring commercial relationships and fee‑for‑service revenue streams.
Neuronetics reported a Q2 2025 loss per share of $0.15 versus a forecast of $0.08, but revenue of $38.1 million exceeded expectations of $36.59 million. The company remains unprofitable, with negative operating and net margins of 34.45% and 43.92% respectively, and is burning cash.
The TMS market is projected to reach $3.33 billion by 2034, underscoring the strategic importance of expanding access to the NeuroStar system. The partnership positions Neuronetics to capture a larger share of the growing market while addressing its financial challenges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.